Abstract
Background: This paper introduces a new clinical test, the Mini Linguistic State Examination (MLSE), as a short assessment for screening and classification of the different manifestations of primary progressive aphasia (PPA). Differentiation and monitoring of PPA variants are vital for management, planning and development of new treatments. The MLSE is designed to improve the uniformity of testing, screening for recruitment to clinical trials, and consistency of research results. It is a brief but effective test which can be adapted to the worlds major languages. Methods: Fifty-four patients and 30 age-, sex- and education-matched controls completed testing with the MLSE and components of the Boston Diagnostic Aphasia Examination in addition to their standard clinical diagnostic assessment. The MLSE includes five domains (motor speech, phonology, semantics, syntax and working memory) that were compared across groups. A random forest classification was used to learn the relationship between these five domains and assess the power of the diagnostic accuracy for predicting PPA subtypes. The final machine learning model was used to create a decision tree to guide the optimal manual classification of patients. Results: On average, the test took less than 20 minutes to administer. Significant group differences were found across all five domains, in terms of the distributions of error-types. These differences mirror the well-known language profiles for the three main PPA variants, which typically require an extended neuropsychology and speech pathology assessment. The random forest prediction model had an overall classification accuracy of 96% (92% for logopenic variant PPA, 93% for semantic variant PPA and 98% for non-fluent variant PPA). The derived decision tree for manual classification produced correct classification of 91% of participants whose data were not included in the training set. Conclusions: The MLSE is a new short cognitive test, with a scoring system that is easy to learn and apply. It is accurate for classifying PPA syndromes, and has potential to screen and monitor language deficits that occur in other focal and neurodegenerative brain disorders associated with language impairment. With increasing importance of language assessment in clinical research, the MLSEs linguistic assessment tool enables the essential profiling of language deficits in a wide clinical community.
Competing Interest Statement
JBR reports consultancy unrelated to the work with Biogen, UCB, Asceneuron and Althira; and receipt of research grants from Janssen, AZ-Medimmune, Lilly unrelated to this work. Remaining authors have no competing interests to declare.
Funding Statement
The research was funded by a Medical Research Council Research Grant award (Ref MR/N025881/1) to PG, MLR JR, KP and SC. Additional support was provided through grants from the MRC (UAG051 and G101400), Wellcome Trust (103838) and ERC (GAP: 670428), and through funding awarded to the National Institute for Health Research Cambridge Biomedical Research Centre and to the MRC CBU (MC_UU_00005/18).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was reviewed and approved by the London (Chelsea) Research Ethics Committee [REC reference: 16/LO/1735]. The study was sponsored by St Georges, University of London, the University of Cambridge and the University of Manchester.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Anonymised data are available on reasonable request for academic purposes.
